Adaptive Biotechnologies Corporation (ADPT)
Adaptive Biotechnologies (ADPT) Surges 12.5%: Is This an Indication of Further Gains?
Adaptive Biotechnologies (ADPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
What Makes Adaptive Biotechnologies (ADPT) a New Buy Stock
Adaptive Biotechnologies (ADPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is Adaptive Biotechnologies (ADPT) Stock Outpacing Its Medical Peers This Year?
Here is how Adaptive Biotechnologies (ADPT) and CVS Health (CVS) have performed compared to their sector so far this year.
Is Adaptive Biotechnologies (ADPT) Outperforming Other Medical Stocks This Year?
Here is how Adaptive Biotechnologies (ADPT) and CVS Health (CVS) have performed compared to their sector so far this year.
Adaptive Biotechnologies (ADPT) is a Great Momentum Stock: Should You Buy?
Does Adaptive Biotechnologies (ADPT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Does Adaptive Biotechnologies (ADPT) Have the Potential to Rally 26.45% as Wall Street Analysts Expect?
The consensus price target hints at a 26.5% upside potential for Adaptive Biotechnologies (ADPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Has Adaptive Biotechnologies (ADPT) Outpaced Other Medical Stocks This Year?
Here is how Adaptive Biotechnologies (ADPT) and Centene (CNC) have performed compared to their sector so far this year.
Adaptive Biotechnologies Corporation (ADPT) Q1 2025 Earnings Call Transcript
Adaptive Biotechnologies Corporation (NASDAQ:ADPT ) Q1 2025 Earnings Conference Call May 1, 2025 4:30 PM ET Company Participants Karina Calzadilla - Head of Investor Relations & FP&A Chad Robins - Chief Executive Officer & Co-Founder Kyle Piskel - Chief Financial Officer Susan Bobulsky - Chief Commercial Officer Conference Call Participants Mark Massaro - BTIG David Westenberg - Piper Sandler Yuko Oku - Morgan Stanley Sebastian Sandler - JPMorgan Tom Stevens - TD Cowen Corey Rosenbaum - Scotia Bank Maggie Boeye - William Blair Operator Good day, and thank you for standing by. Welcome to the Adaptive Biotechnologies First Quarter 2025 Earnings Conference Call.
Adaptive Biotechnologies (ADPT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Adaptive Biotechnologies (ADPT) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Adaptive Biotechnologies (ADPT) Reports Q1 Loss, Tops Revenue Estimates
Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.33 per share a year ago.
Adaptive Biotechnologies (ADPT) Moves to Buy: Rationale Behind the Upgrade
Adaptive Biotechnologies (ADPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Are Medical Stocks Lagging Adaptive Biotechnologies (ADPT) This Year?
Here is how Adaptive Biotechnologies (ADPT) and Castle Biosciences, Inc. (CSTL) have performed compared to their sector so far this year.
